New York, February 5, 2026, 18:10 EST — After-hours trading
- Boston Scientific (BSX) bounced back Thursday, climbing 2.8% following a steep sell-off right after earnings on Wednesday
- Electrophysiology and Watchman sales trends continue to be the main focus following the quarter
- On Feb. 5, Citi and Wells Fargo lowered their price targets but maintained Buy and Overweight ratings
Boston Scientific shares climbed 2.8% Thursday, closing at $77.64. Trading volume hit roughly 38.3 million shares.
The stock found some footing following a sharp drop sparked by earnings that pushed investors to revise their outlook fast. The focus has shifted from the headline beat to concerns over whether the company’s growth drivers are starting to falter.
The stock tumbled as much as 17% on Wednesday, marking its sharpest one-day drop in over 25 years, after the company reported weaker-than-expected Q4 sales in its electrophysiology segment. That unit recorded $890 million in sales, falling short of an RBC-compiled Street estimate of $933 million. Watchman sales also missed estimates, coming in about 1% below consensus, according to analysts cited by Reuters. Citi analyst Joanne Wuensch noted that investors’ concerns “were not misplaced,” even as CEO Michael Mahoney expressed he was “really pleased” with the segment’s 35% organic growth and projects the market will grow roughly 15% in 2026. Reuters
Boston Scientific reported fourth-quarter net sales of $5.286 billion and adjusted earnings of $0.80 per share in its latest quarterly update. The company projects adjusted EPS for 2026 between $3.43 and $3.49, with organic net sales rising 10% to 11%. For the first quarter, it expects adjusted EPS in the range of $0.78 to $0.80 and organic growth between 8.5% and 10%.
A regulatory filing revealed the company submitted that results release to the U.S. Securities and Exchange Commission on Feb. 4.
Boston Scientific’s heart-rhythm business centers on electrophysiology, with pulsed-field ablation devices delivering brief electrical pulses to tackle atrial fibrillation. Investors focus on organic growth, which removes the impact of currency fluctuations and some deal-driven shifts, to assess true demand.
During the earnings call, analysts zeroed in on U.S. electrophysiology after sales stalled quarter over quarter, MedTech Dive reported. J.P. Morgan’s Robbie Marcus was blunt: “This was not the quarter that was hoped for,” signaling doubts about the future path of electrophysiology and Watchman. Still, Mahoney pushed back, saying the company can outpace a market he projects will grow around 15% by 2026 despite rising competition.
Citi lowered its price target for Boston Scientific to $102 from $130 on Thursday but maintained its Buy rating. The firm described the post-earnings drop as “overdone” and viewed current prices as a buying opportunity. TipRanks
Wells Fargo cut its price target on Boston Scientific to $94 from $125 but kept its Overweight rating intact. The downgrade reflects concerns over U.S. electrophysiology and Watchman shortfalls, though the bank still views Boston’s 2026 organic sales growth guidance as within reach.
Boston Scientific outperformed several medtech rivals on Thursday, topping Abbott Laboratories, Medtronic, and Stryker as the broader market slid, MarketWatch reported.
That bounce, however, looks fragile. Should electrophysiology growth decelerate more quickly as procedure volumes stabilize and rivals turn up the pressure, or if Watchman demand remains weak in the U.S., investors may continue to pressure the stock, prompting further target reductions.
On Friday, investors will be looking to see if dip-buying continues and if more companies update their outlooks following earnings calls. The next major milestone comes with first-quarter results, expected around April 22, according to Yahoo Finance.
